logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9623004 B1

PDFFull Text
Date of Patent:
Apr. 18, 2017

Filed:

Jul. 30, 2014

Administration of a therapeutic amount of genistein to mitigate erectile dysfunction resulting from radiation therapy for prostate cancer only throughout a defined administration period commencing shortly before and concluding after radiation therapy

Applicant:

Humanetics Corporation, Minneapolis, MN (US);

Inventors:

Michael D. Kaytor, Maplewood, MN (US);

John L. Zenk, Eden Prairie, MN (US);

Geoffrey E. Schroeder, Woodbury, MN (US);

Zeljko Vujaskovic, Baltimore, MD (US);

Isabel Lauren Jackson, Baltimore, MD (US);

Assignee:

Other;

Attorney:

Sherrill Law Offices, PLLC

Primary Examiner:

T Victor Oh

Int. Cl.
CPC ...
A61K 31/35 (2006.01); A61K 31/353 (2006.01); A61K 9/00 (2006.01); A61K 31/352 (2006.01);
U.S. Cl.
CPC ...
A61K 31/353 (2013.01); A61K 9/006 (2013.01); A61K 31/352 (2013.01);
Abstract

A method for mitigating erectile dysfunction as an adverse side effect of radiation therapy for prostate cancer, comprising administration of a therapeutic dosage of genistein to a patient diagnosed with prostate cancer throughout only a primary administration period that commences a defined period of up to two weeks prior to commencement of radiation therapy for prostate cancer and extends beyond conclusion of the radiation therapy.

Find Patent Forward Citations

Kaytor, Michael. (2017). Administration of a therapeutic amount of genistein to mitigate erectile dysfunction resulting from radiation therapy for prostate cancer only throughout a defined administration period commencing shortly before and concluding after radiation therapy (U.S. Patent No. 9623004). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/9623004

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…